Current Edition

Phase III clinical trials_a fate decider
Volume 11 Issue 6

Phase III Clinical Trials: A Fate Decider in the Drug Development

A Phase III clinical study evaluates the safety, efficacy and related parameters of experimental therapy against a standard therapy in a large human population to …

Continue Reading →
Clinical development in rare diseases
Volume 11 Issue 6

Clinical Development in Rare Diseases: Autoinflammatory Syndrome

”Autoinflammatory” is a term used to describe a group of diseases that cannot be classified as immunological disorders. Autoinflammatory syndromes are a set of genetically …

Continue Reading →
Retooling risk-based mangment
Volume 11 Issue 6

Retooling Risk-based Management Using AI

As a clinical trial monitoring technique, risk-based monitoring (or RBM) has become the R&D industry’s de facto monitoring approach to achieve quality data, patient safety, …

Continue Reading →
Patient pioneers_the patient and site
Volume 11 Issue 6

Patient Pioneers: The Patient- and Site-centricity Movement

The patient-centricity movement has been inspired by the empowerment of patients and patient advocacy groups through the internet, social media and new technology. This has …

Continue Reading →
Driving clinical trials forward
Volume 11 Issue 6

Driving Clinical Trials Forward: The Benefits of Establishing a Strategic Partnership for Flow Cytometry

Targeted therapies for use in clinical studies, such as those in immunooncology (I-O), are the future of pharmaceuticals. Critically assessing the efficacy and safety of …

Continue Reading →
Transforming healthcare_how curative
Volume 11 Issue 6

Transforming Healthcare – How Curative Therapies will Disrupt the Market

The shift to curative treatments promises to transform the entire healthcare ecosystem. Patients whose conditions were previously managed through ongoing, long-term medication can now be …

Continue Reading →